Abstracts tagged "Intervention"

Abstract Number: 2527 • ACR Convergence 2024
Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)
Jacques-Eric Gottenberg¹, Kathy Sivils², Kim Campbell³, Jada Idokogi³, Kim Lo³, Sophia G. Liva³, Jonathan Shelton⁴, Harman Dhatt⁵, Jonathan J. Hubbard³ and Ghaith Noaiseh⁶, ¹Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ²Johnson & Johnson Innovative Medicine, Edmond, OK, ³Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁴Janssen Scientific Affairs, LLC, San Diego, CA, USA, San Diego, ⁵Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, USA, Raritan, NJ, ⁶University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by the presence of specific autoantibodies (AAb) and lymphocytic infiltration of exocrine glandular tissues.…
Abstract Number: 0298 • ACR Convergence 2024
RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults
Miwa Haranaka¹, Akinori Yamada², Saki Takahashi², Keisuke Gotanda², Sonoko Nakano-Kanatani², Nana Uemura², Kensuke Ohnishi², Masanobu Nishidate², Ichio Ohnami² and Megumi Kai³, ¹Souseikai Hakata Clinic, Fukuoka, Japan, ²Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ³Oita University, Oita, Japan
Background/Purpose: Complement C1s is one of the major components of the classical complement pathway (CP), and the abnormal activation of CP is implicated in several…
Abstract Number: 2572 • ACR Convergence 2024
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Remco Erkens¹, Gerda Den Engelsman¹, Sytze De Roock¹, Dörte Hamann¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Mariken Gruppen³, Wineke Armbrust⁴, Elizabeth Legger⁵, Sylvia Kamphuis⁶, Marleen Verkaaik⁷, Ellen Schatorjé⁸, Esther Hoppenreijs⁸, Thomas Vogl⁹, Johannes Roth⁹, Petra Hissink Muller¹⁰, Joost Swart¹, Marc Jansen¹, Jorg van Loosdregt¹¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University Medical Hospital Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, Groningen, Netherlands, ⁶Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁸University Medical Center Radboud, Nijmegen, Nijmegen, Netherlands, ⁹University of Münster, Münster, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…
Abstract Number: 0300 • ACR Convergence 2024
Evaluation of Long-term Primary Patency of Iliocaval Stenting in Patients with Retroperitoneal Fibrosis/chronic Periaortitis
Raymond Lay¹, Sara Achenbach², Cynthia Crowson¹, Umar Ghaffar¹, Michelle Burke¹, Haraldur Bjarnason¹, Newton Neidert¹, Kenneth Warrington¹ and Matthew Koster¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Idiopathic retroperitoneal fibrosis (RPF) / chronic periaortitis (CP) is an uncommon condition characterized by a fibroinflammatory periarterial soft tissue thickening around the infra-renal abdominal…
Abstract Number: 0338 • ACR Convergence 2024
Anti-MDA5 Antibody-positive Dermatomyositis Associated Interstitial Lung Disease – Survival Benefit of Treatment with Rituximab, Janus Kinase Inhibitor and Glucocorticoid Combination in a Prospective Cohort
Cheryl Chun Man Ng¹, Kitty Yan Kwok¹, Chup-Hei Ho¹, Tze-Chung Ho¹, Chu-Oi Ciang² and Moon-Ho Leung¹, ¹Queen Elizabeth Hospital, Hong Kong, Hong Kong, ²QEH, Hong Kong., Hong Kong, China
Background/Purpose: Anti-melanoma differentiation-associated protein 5 antibody associated dermatomyositis (Anti-MDA5 DM) is known to be an aggressive disease. Earlier cohorts reported a 1-year mortality of 38%-57%, with rapidly…
Abstract Number: 0426 • ACR Convergence 2024
Quality Improvement Initiative to Increase Contraception Screening and Documentation for Reproductive-Aged Women Prescribed Teratogenic Medications in an Academic Rheumatology Center
Caroline Siegel¹, Avi Mikhaylov¹, Emily Wu², Deanna Jannat-Khah¹, Erika Abramson³, Lisa Sammaritano⁴ and Nancy Pan⁵, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Rochester, NY, ³Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, Scarsdale, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Rheumatology patients prescribed teratogenic medications often are not prescribed effective contraception. Efforts to improve this important quality indicator are limited by inadequate and poorly…
Abstract Number: 0672 • ACR Convergence 2024
Pharmacokinetics (PK), Effectiveness and Safety of Open-label (OL) Tofacitinib for the Treatment of Moderate to Severe Skin Involvement in Young Adults with SLE
Ivanna Romankevych¹, Nora Singer², Kaliyani Marathe³, Angela Merritt¹, Ekemini Ogbu⁴, Chen Chen⁵, Megan Quinlan-Waters¹, Kathleen Pelletier⁶, Haihong Shi⁶, Xiaoxing Wang⁶, Bin Huang⁷ and hermine brunner⁴, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, DC, ⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cin, OH, ⁶Pfizer Inc, Groton, CT, ⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH
Background/Purpose: Many cytokines implicated in lupus pathogenesis depend on JAK signaling to exert their intracellular action. Tofacitinib (TOFA) inhibits signaling by cytokine receptors associated with…
Abstract Number: 1053 • ACR Convergence 2024
Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases
Kai Sun¹, Lisa Carnago², Isaac Smith³, Brian Andonian¹, Stephen Balevic¹, Ankoor Shah¹, Catherine Sims⁴, Kathryn Pollak⁵, Amy Corneli⁵, Hayde Bosworth⁵ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke Health, Hillsborough, NC, ³Duke University Hospital, Durham, NC, ⁴Duke University, Knightdale, NC, ⁵Duke University, Durham, ⁶Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is as high as 75% among patients with rheumatic diseases, leading to increased morbidity, mortality, and cost. Existing adherence interventions tend to…
Abstract Number: 1058 • ACR Convergence 2024
Bridging the Care Gap Between Hospital Discharge and Outpatient Care Transition for Pediatric Rheumatology Patients: An RN-led Quality Improvement Project
Adrienne Ramirez¹, Lisa Walker-Vischer² and Tzielan Lee³, ¹Stanford Medicine - Children's Health, Palo Alto, CA, ²San Jose State University, Campbell, CA, ³Stanford University School of Medicine, Palo Alto, CA

Background/Purpose: When pediatric rheumatology patients are discharged from a hospital, the period between hospital discharge & outpatient care transition creates a care gap when there…
Abstract Number: 1063 • ACR Convergence 2024
AI –Driven Precision in Rheumatologic Emergencies: Unveiling the Capability of Top Healthcare Chatbots
Abi Fadairo-Azinge¹, Jinoos Yazdany² and Matt Sakumoto³, ¹University of California San Francisco UCSF, SAN-FRANCISCO, CA, ²University of California San Francisco, San Francisco, CA, ³Sutter Health Virtual-First Primary Care Physician & CMIO Sutter West Bay Region Sutter Health,Assistant Clinical Professor,Department of Medicine, UCSF, SAN-FRANCISCO, CA
Background/Purpose: Rheumatologic emergencies are severe, with mortality rates up to 50% even with timely intervention. Associated morbidity includes permanent organ failure and significant disability. This…
Abstract Number: 1065 • ACR Convergence 2024
A Quality Improvement Project to Improve Contraception Management in Patients with Systemic Lupus Erythematosus on Teratogenic Medications
Marta Bean¹, Brian Coburn¹, Thomas Riley², Elise Breed¹, Carlos M García-González¹, Akash Gupta¹, Jonathan Kotzin¹, Adam Mayer³, John Oghene¹, Ellen Romich⁴, Michael George¹, Rachel Dayno¹, Nora Sandorfi¹, Preethi Thomas¹ and Anupama Shahane¹, ¹University of Pennsylvania, Philadelphia, PA, ²Hopsital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁴University of Pennsylvania, Media, PA
Background/Purpose: Many patients with systemic lupus erythematosus (SLE) require teratogenic medications for management of their disease. Reliable contraception is important to avoid unintended pregnancy in…
Abstract Number: 1179 • ACR Convergence 2024
Development of an Optimal Physiotherapy Intervention to Reduce Stiffness Following Knee Joint Replacement
Michelle Hall¹, Fiona Moffatt¹, Ben Smith², Melanie Narayanasamy³, Joanne Stocks¹, Katie Sheehan⁴ and Catherine Sackley³, ¹University of Nottingham, Nottingham, United Kingdom, ²University Hospitals of Derby and Burton NHS Foundation Trust, Derby, England, United Kingdom, ³University of Nottingham, Nottingham, England, United Kingdom, ⁴Queen Mary University of London, London, England, United Kingdom
Background/Purpose: Arthrofibrosis is a complication following knee joint replacement due to excessive scar tissue formation. It leads to knee stiffness, restricted range of movement (ROM)…
Abstract Number: 1186 • ACR Convergence 2024
Intra-articular Corticosteroid Injections for Knee Osteoarthritis: Does the Dose Matter?
Neenu Sukumaran¹ and John Waterman², ¹University of Connecticut, Avon, CT, ²Veterans Administration, Simsbury, CT
Background/Purpose: Intra-articular(IA) corticosteroid injections for knee osteoarthritis (OA) have been performed for over 60 years. However, the appropriate dose of IA corticosteroids has not been determined. To…
Abstract Number: 1299 • ACR Convergence 2024
Board-Style Rheumatology Teaching for Medicine Residents: Novel Approach to Curriculum Development
Merve Aksoy*, Shadi Jafari-Esfahani*, Yasaman Ahmadzadeh and Katarzyna Gilek-Seibert, Roger Williams Medical Center, Providence, RI
Background/Purpose: During their training, internal medicine (IM) residents often have limited exposure to rheumatology, resulting in decreased confidence levels and inadequate scores on the In-training…
Abstract Number: 1666 • ACR Convergence 2024
Preliminary Effects of a Fully-Remote Online Physical Activity Program Following Knee Replacement
Scott Jamieson¹, Jessica Unick², Kailyn Horn¹, Halle Prine¹, Chih-Hsiang Yang¹ and Christine Pellegrini¹, ¹University of South Carolina, Columbia, SC, ²Brown Alpert Medical School at Brown University, Providence, RI
Background/Purpose: After knee replacement (KR), most adults fail to meet recommended levels of physical activity. Virtual options to promote physical activity in clinical populations have…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].